BACKGROUND: Newly emerged mutations within the Plasmodium falciparum chloroquine resistance transporter (PfCRT) can confer piperaquine resistance in the absence of amplified plasmepsin II (pfpm2). In this study, we estimated the prevalence of co-circulating piperaquine resistance mutations in P. falciparum isolates collected in northern Cambodia from 2009 to 2017. METHODS: The sequence of pfcrt was determined for 410 P. falciparum isolates using PacBio amplicon sequencing or whole genome sequencing. Quantitative polymerase chain reaction was used to estimate pfpm2 and pfmdr1 copy number. RESULTS: Newly emerged PfCRT mutations increased in prevalence after the change to dihydroartemisinin-piperaquine in 2010, with >98% of parasites harboring these mutations by 2017. After 2014, the prevalence of PfCRT F145I declined, being outcompeted by parasites with less resistant, but more fit PfCRT alleles. After the change to artesunate-mefloquine, the prevalence of parasites with amplified pfpm2 decreased, with nearly half of piperaquine-resistant PfCRT mutants having single-copy pfpm2. CONCLUSIONS: The large proportion of PfCRT mutants that lack pfpm2 amplification emphasizes the importance of including PfCRT mutations as part of molecular surveillance for piperaquine resistance in this region. Likewise, it is critical to monitor for amplified pfmdr1 in these PfCRT mutants, as increased mefloquine pressure could lead to mutants resistant to both drugs.
BACKGROUND: Newly emerged mutations within the Plasmodium falciparum chloroquine resistance transporter (PfCRT) can confer piperaquine resistance in the absence of amplified plasmepsin II (pfpm2). In this study, we estimated the prevalence of co-circulating piperaquine resistance mutations in P. falciparum isolates collected in northern Cambodia from 2009 to 2017. METHODS: The sequence of pfcrt was determined for 410 P. falciparum isolates using PacBio amplicon sequencing or whole genome sequencing. Quantitative polymerase chain reaction was used to estimate pfpm2 and pfmdr1 copy number. RESULTS: Newly emerged PfCRT mutations increased in prevalence after the change to dihydroartemisinin-piperaquine in 2010, with >98% of parasites harboring these mutations by 2017. After 2014, the prevalence of PfCRT F145I declined, being outcompeted by parasites with less resistant, but more fit PfCRT alleles. After the change to artesunate-mefloquine, the prevalence of parasites with amplified pfpm2 decreased, with nearly half of piperaquine-resistant PfCRT mutants having single-copy pfpm2. CONCLUSIONS: The large proportion of PfCRT mutants that lack pfpm2 amplification emphasizes the importance of including PfCRT mutations as part of molecular surveillance for piperaquine resistance in this region. Likewise, it is critical to monitor for amplified pfmdr1 in these PfCRT mutants, as increased mefloquine pressure could lead to mutants resistant to both drugs.
Authors: Geraldine A Van der Auwera; Mauricio O Carneiro; Christopher Hartl; Ryan Poplin; Guillermo Del Angel; Ami Levy-Moonshine; Tadeusz Jordan; Khalid Shakir; David Roazen; Joel Thibault; Eric Banks; Kiran V Garimella; David Altshuler; Stacey Gabriel; Mark A DePristo Journal: Curr Protoc Bioinformatics Date: 2013
Authors: Mark A DePristo; Eric Banks; Ryan Poplin; Kiran V Garimella; Jared R Maguire; Christopher Hartl; Anthony A Philippakis; Guillermo del Angel; Manuel A Rivas; Matt Hanna; Aaron McKenna; Tim J Fennell; Andrew M Kernytsky; Andrey Y Sivachenko; Kristian Cibulskis; Stacey B Gabriel; David Altshuler; Mark J Daly Journal: Nat Genet Date: 2011-04-10 Impact factor: 38.330
Authors: Nonlawat Boonyalai; Brian A Vesely; Chatchadaporn Thamnurak; Chantida Praditpol; Watcharintorn Fagnark; Kirakarn Kirativanich; Piyaporn Saingam; Chaiyaporn Chaisatit; Paphavee Lertsethtakarn; Panita Gosi; Worachet Kuntawunginn; Pattaraporn Vanachayangkul; Michele D Spring; Mark M Fukuda; Chanthap Lon; Philip L Smith; Norman C Waters; David L Saunders; Mariusz Wojnarski Journal: Malar J Date: 2020-07-25 Impact factor: 2.979
Authors: William L Hamilton; Roberto Amato; Rob W van der Pluijm; Christopher G Jacob; Huynh Hong Quang; Nguyen Thanh Thuy-Nhien; Tran Tinh Hien; Bouasy Hongvanthong; Keobouphaphone Chindavongsa; Mayfong Mayxay; Rekol Huy; Rithea Leang; Cheah Huch; Lek Dysoley; Chanaki Amaratunga; Seila Suon; Rick M Fairhurst; Rupam Tripura; Thomas J Peto; Yok Sovann; Podjanee Jittamala; Borimas Hanboonkunupakarn; Sasithon Pukrittayakamee; Nguyen Hoang Chau; Mallika Imwong; Mehul Dhorda; Ranitha Vongpromek; Xin Hui S Chan; Richard J Maude; Richard D Pearson; T Nguyen; Kirk Rockett; Eleanor Drury; Sónia Gonçalves; Nicholas J White; Nicholas P Day; Dominic P Kwiatkowski; Arjen M Dondorp; Olivo Miotto Journal: Lancet Infect Dis Date: 2019-07-22 Impact factor: 71.421
Authors: Jonathan Kim; Yong Zi Tan; Kathryn J Wicht; Satchal K Erramilli; Satish K Dhingra; John Okombo; Jeremie Vendome; Laura M Hagenah; Sabrina I Giacometti; Audrey L Warren; Kamil Nosol; Paul D Roepe; Clinton S Potter; Bridget Carragher; Anthony A Kossiakoff; Matthias Quick; David A Fidock; Filippo Mancia Journal: Nature Date: 2019-11-27 Impact factor: 49.962